-
Day One Pharmaceuticals NASDAQ:DAWN Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers. Day One was founded to address a critical unmet need: children with cancer are being left behind in a cancer drug development revolution. Its name was inspired by the “The Day One Talk”1 that physicians have with patients and their families about an initial cancer diagnosis and treatment plan. The company aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One. Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important emerging cancer treatments. The Company’s lead product candidate, DAY101, is an oral, highly-selective type II pan-RAF kinase inhibitor, and is being evaluated in a pivotal Phase 2 clinical trial (FIREFLY-1) in pediatric, adolescent and young adult patients with recurrent or progressive low-grade glioma (pLGG). The Company’s pipeline also includes the investigational agent pimasertib, a clinical-stage, oral, small molecule found to selectively inhibit mitogen-activated protein kinase kinases 1 and 2 (MEK). Through Day One and its collaborators, cancer drug development comes of age. Day One is based in South San Francisco.
Location: 395 Oyster Point Boulevard, Suite 217, CA, 94080, US | Website: dayonebio.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
736.1M
Cash
558.4M
Avg Qtr Burn
-22.37M
Short % of Float
28.08%
Insider Ownership
17.01%
Institutional Own.
93.23%
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
OJEMDA™ (Tovorafenib) (DAY101) (pan-RAF inhib) Details Cancer, Pediatric low-grade glioma | Approved Quarterly sales | |
MTX-13 (DAY301) Details Solid tumor/s | Phase 1 Initiation | |
Tovorafenib (DAY101) +/- Pimasertib Details Solid tumor/s, Cancer | Failed Discontinued |